Israeli cancer detection company Nucleix wins €2.5m EU grant

Nucleix has received the funding for Lung EpiCheck, a screening diagnostic blood test for early detection of lung cancer. Israeli cancer detection and screening company Nucleix announced today that it has received €2.5 million in funding, following its application to the highly-selective EIC pilot SME Instrument Phase II European program. EIC pilot SME Instrument Phase 2 is part of Horizon 2020, a €80 billion funding program managed by the European Commission and dedicated to innovation and research.

SOCIAL MEDIA

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the
email and you’re good to go.

GOT IT !